Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crolibulin

Drug Profile

Crolibulin

Alternative Names: Crinobulin; Crolibulin; EP2407; EPC 2407; MX-2407; MX116407

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc; National Cancer Institute (USA)
  • Class Antineoplastics; Benzopyrans; Nitriles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Microtubule protein inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Lymphoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma in USA (IV, Infusion)
  • 31 Dec 2016 Immune Pharmaceuticals completes a phase I/II trial for Solid tumours (Combination therapy, In adults, In the elderly, Recurrent, Metastatic, Inoperable/Unresectable, Second-line therapy or greater) in the USA (IV) (NCT01240590)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top